Main menu

Cancer clinical genomic testing using Oxford Nanopore whole-genome sequencing | LC26

  • Published on:

Abstract
Whole-genome sequencing (WGS) is currently offered as a routine genomic test for selected cancer clinical indications through the NHS Genomic Medicine Service. Here, we investigate the requirements to support the introduction of Oxford Nanopore Technologies (ONT) WGS into the NHS and assess the clinical benefits for cancer patients. Four hundred and ninety-nine tumour-normal pairs (brain, leukaemia, and sarcoma tumours) were sequenced with the PromethION platform across five NHS Genomics Laboratory Hubs. The quality of fresh frozen samples collected through clinical pathways was sufficient to generate high-depth coverage (tumour ≥40x, normal ≥20x) for accurate variant detection. Analysis of the underperforming samples identified key contributing factors, such as DNA extraction method, insufficient DNA, and fragmentation. Iterative improvements to our analytical pipeline led to high accuracy of detection for all types of genomic variants (sensitivity and specificity exceed 95%, except 89% sensitivity for indels). Methylation-based classification achieved 91% concordance with integrated pathology diagnosis for brain tumours. The strongest evidence of clinical utility emerged for brain tumours where ONT sequencing can consolidate multiple molecular tests including methylation profiling into a single workflow, minimizing turnaround times. For other tumours, ONT sequencing has shown promise in resolving complex cases, e.g. detecting clinically relevant events missed by other tests in about 10% of haematological tumours. Additional benefits included detection of mid-sized indels and variants in challenging genomic regions or cryptic chromosomal rearrangements, and phasing compound heterozygous variants. In summary, our study has demonstrated the value of ONT WGS, particularly a ‘one-stop-shop’ test for brain tumours as well as a second-line test for selected cancer cases.

Biography
Rowan Howell is a Senior Genomics Data Scientist at Genomics England, where he works on bioinformatics analysis of long-read genomics data. He completed a PhD in computational biology between the Francis Crick Institute and King’s College, London before conducting postdoctoral research at the Cancer Institute, UCL. While at Genomics England, Rowan has overseen analysis of the Cancer 2.0 long-reads project, examining the clinical utility of ONT for cancer genomics.

Authors: Rowan Howell

Getting started

Buy a MinION starter pack Nanopore store Sequencing Service providers Channel Partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Modern slavery policy Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditation
English flag